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Abstract
Ewing Sarcoma is the second most common primary bone sarcoma with 900 new diagnoses per year in Europe
(EU27). It has a poor survival rate in the face of metastatic disease, with no more than 10% survival of the 35%
who develop recurrence. Despite the remaining majority having localised disease, approximately 30% still relapse
and die despite salvage therapies. Prognostic factors may identify patients at higher risk that might require
differential therapeutic interventions. Aside from phenotypic features, quantitative biomarkers based on biological
measurements may help identify tumours that are more aggressive. We audited the research which has been done
to identify prognostic biomarkers for Ewing sarcoma in the past 15 years. We identified 86 articles were identified
using defined search criteria. A total of 11,625 patients were reported, although this number reflects reanalysis of
several cohorts. For phenotypic markers, independent reports suggest that tumour size > 8 cm and the presence
of metastasis appeared strong predictors of negative outcome. Good histological response (necrosis > 90%) after
treatment appeared a significant predictor for a positive outcome. However, data proposing biological biomarkers
for practical clinical use remain un-validated with only one secondary report published. Our recommendation is
that we can stratify patients according to their stage and using the phenotypic features of metastases, tumour size
and histological response. For biological biomarkers, we suggest a number of validating studies including markers
for 9p21 locus, heat shock proteins, telomerase related markers, interleukins, tumour necrosis factors, VEGF
pathway, lymphocyte count, and a number of other markers including Ki-67.
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Introduction
Ewing sarcoma is the second most common primary
bone sarcoma. It is an orphan state disease with
approximately 900 new diagnoses a year in Europe [1].
It is also called the Ewing Sarcoma Family of Tumours
(ESFT) and includes Ewing sarcoma of bone, extra-oss-
eous Ewing sarcoma, Primitive Neuroectodermal
(PNET) and Askin’s tumours. Ewing sarcoma is diagnos-
tically defined by a Ewing sarcoma EWS (chromosome
22) translocation resulting in fusion with an ETS tran-
scription factor, the commonest abnormality (85%)
being EWS-FLI1 (chromosome 11). Ewing sarcoma is a
disease affecting children and young adults with a peak
incidence at age fifteen. With current treatment options
the 5 year survival for non-metastatic disease is 60-70%.
However, survival for the 25% of patients that present
with metastatic disease is approximately 20% [2], and
for those who develop relapsed and/or refractory dis-
ease, the survival is no more than 10%.
Current patients are subdivided by disease stage,
namely non-metastatic, metastatic and recurrence, and
patients in each group are treated the same. But appar-
ently this subdivision is not always related to clinical
outcome, because of the patients who present with non-
metastatic disease, approximately 30% die within 5
years. This group may be currently undertreated while
the 70% who survive may be over-treated. It may there-
fore be important to separate the high risk patients
from the low risk patients and to be able to detect che-
motherapy resistance and metastases early.
A way of predicting patients’ outcome is by using
prognostic factors. The most commonly used are clinical
features, eg age, gender, metastases. Biomarker is a
synonym for biological markers and is defined as “a
characteristic that is objectively measured and evaluated
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genic processor or pharmacologic responses to a thera-
peutic intervention” [3]. Biomarkers are currently
already being used for screening, diagnosis, prognosis
and monitoring of cancer patients. In 2005 the Report-
ing recommendations for tumour MARKer prognostic
studies (REMARK) guidelines were published [4]. The
goal of these guidelines is to make the results from clin-
ical prognostic studies transparent and to improve the
level of comparison that is possible between studies.
We report an overview of the research which has been
done to identify reliable biomarkers for Ewing sarcoma
in the past 15 years, where we detail the kind of markers
that have been tested, the number of patients involved
and the p-value showing the significance of the marker.
The results highlight some interesting biomarkers, but
they have yet to be validated.
Materials and methods
Search strategy
We report data available in the public domain only. Papers
were identified from PubMed searches and from refer-
ences in the found articles. The search algorithm was:
(Ewing sarcoma) AND (prognostic factors) OR (biomar-
ker). Only papers published between 1995 and 2010 are
included. The latest search was done in June 2010. When-
ever multiple reports from the same study were published,
we used only the report with the latest published date to
avoid any duplication of information. Papers were eligible
if they: (1) described (or cited a paper that described) a
Ewing sarcoma study of prognostic factors or biomarkers;
(2) were published in English; and (3) came from indus-
trialized countries. All types of evaluation were accepted
(full papers, conference abstracts, reports) as long as
results (including data) were presented.
Data extraction
Data extraction was conducted independently by the
first author (A.M. v. M.). We used a systematic method
for the search normally used for meta-analysis [5]. Dif-
ferences in data extraction were resolved by consensus
with a second author (A.B.H). From each eligible trial
we recorded authors’ names, journal and year of publi-
cation and the results from the study.
Results and Discussion
Eligible trials
A flow-chart indicating the identification of reports for
inclusion in the analysis is reported for Ewing sarcoma
(Figure 1). During the search many reports had to be
excluded mainly because no prognostic markers were
reported in the article. When we searched the reports
using full text, we had to exclude some papers because
no Ewing sarcoma patients were included in these
reports. We identified 86 articles which were eligible for
our search criteria. In these papers a total of 11, 625
patients were reported.
In this report we looked at the published data on the
use of biomarkers for the last 15 years. Biomarkers were
grouped into phenotypic markers and biological mar-
kers. Markers were taken as statistically significant if p <
0.05. For phenotypic markers we reported the outcome
for gender, tumour size, presence of metastases and his-
tological response after treatment (Tables 1, 2, 3 &4).
We showed the p-value reported in the eligible articles
and the distribution of p correlated to the number of
patients (Figures 2). There doesn’t seem to be a relation-
ship between the number of patients and the p-value.
For example, the distribution of histological response
shows that the studies with small patient numbers have
the same statistical significance as these with large
patient numbers. Throughout this report, the assump-
tion is that the biomarker has a linear relationship to
outcome. We know that for many biomarkers, this is
not the case. For example, data transformation using
either bicubic splines or fractional polynomials is often
required to correlate continuous relationships between
biomarkers and outcome, as opposed to predefined cut-
points [6]. We can only have limited extrapolation of
the reported data to outcome as in most instances these
questions have not been addressed.
Primary outcome
The investigated biomarkers are subdivided in two
groups, phenotypic markers and biological markers. For
Figure 1 Flowchart for the identification of eligible reports.
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and histological response are reported in Tables 1, 2, 3
and 4. For all these phenotypic markers we compared
the patient number and p-value, in which p < 0.05 was
taken as statistically significant. However we weren’t
able to retrieve the p-value in all articles, sometimes it
was only mentioned as being significant or non-signifi-
cant. For each phenotypic marker we looked at the dif-
ferences in overall survival between: for gender, men vs
women; for tumour size, < 8-10 cm vs > 8- 10 cm; for
metastasis presence at initial presentation vs absence
and for histological response, > 90% necrosis vs < 90%
necrosis. Distributions of p related to patient numbers
in these four phenotypic markers are shown in Figures
2. For these four phenotypic markers we show that
there is no correlation between the number of patients
and the statistical significance of the outcome. More
phenotypic markers were reported: fusion type, ethni-
city, performance status and margins. However because
of the low number of studies which reported these out-
comes these results are not shown in detail. In 26 arti-
cles the impact of tumour site on the overall survival is
shown, but because sites are compared in different ways
it is difficult to summarize these findings.
Currently clinical stage is being used to determine
whether a patient has a high or low risk for developing
metastases or recurrence. However, it seems that clini-
cal stage is not always related to outcome, because of
the patients who present with non-metastatic disease,
only 70% of them survive for 5-years. Therefore, what
is the difference between the 70% of the patients who
s u r v i v ea n dt h e3 0 %w h od o n ’t? Can one somehow
foretell chemotherapy resistance and detect metastases
early? One way to predict the outcome of patients
apart from clinical stage is to use biomarkers. These
are objective measurements which reflect biological
processes. The biomarkers currently being used are
tumour size and the presence of metastases. Biological
markers are not being used, even though they may
p r o v i d eaw a yt op r e d i c tap a t i e n t ’so u t c o m em o r e
accurately than phenotypic markers. From the results
for phenotypic markers we can see that gender is
probably not significant important for patient outcome.
In 15 articles we found 11 reports that gender is non-
significant. Tumour size > 8 cm seems to be impor-
tant, with 15 out of 22 articles finding it to be a pre-
dictor and significantly related to negative outcome.
T h ep r e s e n c eo fm e t a s t a s i si sas t r o n gp r e d i c t o ro f
negative outcome with 24 articles reporting it as signif-
icantly relevant compared to only 3 reporting it as
non-significant. For histological response, 12 out of 16
Table 1 Outcome for phenotypic marker: gender
Author Year Pt
number
P
Craft et al, Eur J Cancer 33 (7), 1061-9[8] 1997 142 0.3
Aparicio et al, Oncology 55, 20-6 [9] 1998 116 NS
Ahrens et al, Med Pediatr Oncol 32, 186-95 [10] 1999 177 0.92
Ginsberg et al, J Clin Oncol 17, 1809-14[11] 1999 85 0.79
Givens et al, Int J Oncol 14 (6), 1039-43[12] 1999 85 NS
Bacci et al, J Clin Oncol 18, 4-11[13] 2000 359 0.02
Jenkin et al, Med Pediatr Oncol 37, 383-9[14] 2001 93 0.73
Krasin et al, Cancer 104, 367-73[15] 2005 33 0.25
Bacci et al, Acta Oncol 45, 469-75[16] 2006 579 0.03
De Angulo et al, J Pediatr Hematol Oncol 29
(1), 48-52[17]
2007 24 NS
Leavey et al, Pediatr Blood Cancer 51 (3), 334-8
[18]
2008 262 0.05
Jawad et al, Cancer 115, 3526-36[19] 2009 1631 0.004
Kikuta et al, Clin Cancer Res 15 (8), 2885-94[20] 2009 8 0.53
Sari et al, Pediatr Blood Cancer 54, 19-24[21] 2010 87 0.04
Xie et al, Chin J Cancer 29 (4), 420-4 2010 18 0.36
NS: not significant
Table 2 Outcome for phenotypic marker: tumour size
Author Year Pt
number
P
Aparicio et al, Oncology 55, 20-6[9] 1998 116 0.0016
Kawai et al, Cancer 82, 851-9[22] 1998 20 0.0038
Ahmad et al, Cancer 85, 725-31[23] 1999 24 0.277
Givens et al Int J Oncol 14 (6), 1039-43[12] 1999 85 NS
Cotterill et al, J Clin Oncol 18, 3108-14[24] 2000 975 0.001
De Alava et al, Cancer 89, 783-92[25] 2000 55 0.02
Jenkin et al, Med Pediatr Oncol 37, 383-9[14] 2001 93 0.0001
Oberlin et al, B J Cancer 85 (11), 1646-54[26] 2001 141 0.002
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 13 0.05
Krasin et al, Pediatr Blood Cancer 43, 229-36
[28]
2004 37 S
Matsunobu et al, Clin Cancer Res 10, 1003-12
[29]
2004 21 0.05
Krasin et al, Cancer 104, 367-73[28] 2005 33 0.25
Aksnes et al, Acta Oncol 45, 38-46[30] 2006 56 0.001
Bacci et al, Acta Oncol 45, 469-75[16] 2006 579 0.0004
Mikulic et al, J Pediatr Surg 41, 524-9[31] 2006 27 0.031
Cheung et al, Clin Cancer Res 13 (23), 6978-83
[32]
2007 28 NS
Rodriguez-Galindo et al, Ann Oncol 19, 814-20
[33]
2008 220 0.018
Yonemori et al, J Cancer Res Clin Oncol 134,
389-95[34]
2008 79 S
Jawad et al, Cancer 115, 3526-36[19] 2009 1631 0.001
Kikuta et al, Clin Cancer Res 15 (8), 2885-94
[20]
2009 8 0.018
Lee et al, Cancer 116, 1964-73[35] 2010 725 0.001
Xie et al, Chin J Cancer 29 (4), 420-4 2010 18 0.44
NS: not significant, S: significant
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significant predictor for positive outcome.
For some phenotypic markers it is unclear how the
cut-off point between predictor of positive or negative
outcomes is determined. For tumour size the cut-off
point for negative outcome is > 8 cm, but it is undefined
how this is selected. It seems more logical that tumour
size is a continuous variable with an increasingly nega-
tive outcome with increasing size. The same can prob-
ably be said for age and surgical margins.
Biological markers are more difficult to compare,
because for most of these markers only one or two
reports are published. We grouped the biological mar-
kers according to their function and we ended up with
5 groups, namely cell cycle, karyotype, immunological,
blood products and the remaining biological markers
which couldn’t be classified in one of the other groups.
The results from the biological markers are shown in
Tables 5, 6, 7, 8 and 9. The correlation between patient
number and statistical significance of the outcome for
t h ef i v eg r o u p si ss h o w ni nF i g u r e s3 .W es h o wt h a t
there is no correlation between the patient number and
the statistical significance of the outcome. It appears
Table 3 Outcome for phenotypic marker: metastases
Author Year Pt
number
P
Terrier et al, Eur J Cancer 31 (3), 307-14[36] 1995 315 0.003
Terrier et al, Semin Diagn Pathol 13 (3), 250-7
[37]
1996 315 S
Aparicio et al, Oncology 55, 20-6[9] 1998 116 0.03
De Alava et al, J Clin Oncol 16 (4), 1248-55[38] 1998 99 0.008
Paulussen et al, J Clin oncol 16 99), 3044-52
[39]
1998 114 S
Ahmad et al, Cancer 85, 725-31[23] 1999 24 0.219
Baldini et al, Ann Surg 230 (1), 79-86[40] 1999 37 0.002
Ginsberg et al, J Clin Oncol 17, 1809-14[11] 1999 85 0.33
Luksch et al, Tumori 85 (2), 101-7[41] 1999 73 S
Cotterill et al, J Clin Oncol 18, 3108-14[24] 2000 975 0.0001
De Alava et al, Cancer 89, 783-92[25] 2000 55 0.02
Wei et al, Cancer 89, 793-9[42] 2000 39 0.001
Jenkin et al, Med Pediatr Oncol 37, 383-9[14] 2001 93 0.04
Zielenska et al, Cancer 91, 2156-64[43] 2001 26 0.0137
Martin et al, Arch Surg 138, 281-5[44] 2003 59 0.02
Fuchs et al, Clin Cancer Res 10, 1344-53[45] 2004 31 0.022
Matsunobu et al, Clin Cancer Res 10, 1003-12
[29]
2004 21 NS
Weston et al, B J Cancer 91, 225-32[46] 2004 385 0.001
Aksnes et al, Acta Oncol 45, 38-46[30] 2006 56 0.001
Kreuter, Eur J Cancer 45, 1904-11[47] 2006 40 S
La et al, Int J Radiat Oncol Biol Phys 64 (2),
544-50[48]
2006 60 0.036
Cheung et al, Clin Cancer Res 13 (23), 6978-83
[32]
2007 28 0.04
Leavey et al, Pediatr blood Cancer 51 (3), 334-
8[18]
2008 262 0.02
Yonemori et al, J Cancer Res Clin Oncol 134,
389-95[34]
2008 79 0.02
Jawad et al, Cancer 115, 3526-36[19] 2009 385 0.001
Sari et al, Pediatr Blood Cancer 54, 19-24[21] 2010 87 0.001
Xie et al, Chin J Cancer 29 (4), 420-4 2010 18 0.01
NS: not significant, S: significant
Table 4 Outcome for phenotypic marker: histological
response
Author Year Pt
number
P
Delepine et al, J Chemother 9 (5), 352-63[49] 1997 39 0.05
Picci et al, J Clin Oncol 15 (4), 1553-9[50] 1997 118 0.0001
Aparicio et al, Oncology 55, 20-6[9] 1998 116 0.018
Paulussen et al, J Clin Oncol 16 (9), 3044-52
[39]
1998 114 S
Abudu et al, J Bone Joint Surg 81 (2), 317-22
[51]
1999 50 0.03
Ahrens et al, Med Pediatr Oncol 32, 186-95
[10]
1999 177 0.27
Baldini et al, Ann Surg 230 (1), 79-86[40] 1999 37 0.01
Bacci et al, J Clin Oncol 18, 4-11[13] 2000 359 0.001
De Alava et al, Cancer 89, 783-92[25] 2000 55 0.001
Ohali et al, J Clin Oncol 21, 3836-43[52] 2003 31 0.0001
Scotlandi et al, Eur J Cancer 41, 1349-61[53] 2005 113 0.05
Bacci et al, Acta Oncol 45, 469-75[16] 2006 579 0.0005
Mikulic et al, J Pediatr Surg 41, 524-9[31] 2006 27 0.047
Avigad et al, Clin Cancer Res 13 (19), 5777-83
[54]
2007 32 0.13
Yonemori, J Cancer Res Clin Oncol 134, 389-
95v [34]
2008 79 0.04
Meynet et al, Cancer Res 70 (9), 3730-8[55] 2010 97 0.02
S: significant
Figure 2 Distribution of p related to patient number for the
phenotypic markers: gender, tumour size, metastases and
histological response. The red line shows the cut-off point of p =
0.05.
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Author Year Biomarker Pt number P
Landanyi et al, J Pathol 175 (2), 211-7 1995 MDM-2 30 0.005
Luksch et al, Tumori 85 (2), 101-7[41] 1999 Mitose presence 73 S
Sollazzo et al, tumori 85 (3), 167-73[56] 1999 Ki-67 38 0.01
De Alava et al, Cancer 89, 783-92[25] 2000 Ki-67 55 0.005
Abudu et al, Br J Cancer 79(7-8), 1185-9[57] 1999 P53 50 0.02
Huang et al, J Clin Oncol 23, 548-58[58] 2005 P53 60 0.001
Matsunobu et al, C;in Cancer Res 10, 1003-12[29] 2004 P27 21 0.01
Wei et al, Cancer 89, 793-9[42] 2000 INK4a 39 0.001
Maitra et al, Arch Pathol Lab Med 125, 1207-12[59] 2001 P16INK4a 20 0.41
Maitra et al, Arch Pathol Lab Med 125, 1207-12[59] 2001 P14ARF 20 NS
Huang et al, J Clin Oncol 23, 548-58[58] 2005 P16/p14ARF 60 0.03
Maitra et al, Arch Pathol Lab Med 125, 1207-12[59] 2001 P21WAF1 20 0.61
Ohali et al, Oncogene 23, 8997-9006[60] 2004 Cadherin-11 20 0.024
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] 2007 STEAP1 28 0.0012
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] 2007 CCND1 28 0.0077
Martins et al, Cancer Res 68 (15), 6260-70[61] 2008 Heat shock 90 54 S
Zanini et al, Virchows Arch 452, 157-67[62] 2008 Heat shock 27 unknown NS
S: significant, NS: not significant
Table 6 Outcome for biological markers: karyotype
Author Year Biomarker Pt number P
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41 1999 1q 28 NS
Hattinger et al, Br J Cancer 86, 1763-9[63] 2002 1q 134 0.046
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41 1999 6p2.1 28 0.004
Lopez-Guerrero et al, Lab Invest 81 (6), 803-14[64] 2001 9p21 locus 19 0.005
Hattinger et al, Br J Cancer 86, 1763-9[63] 2002 16q 134 0.008
Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54[65] 1999 Chr 1 58 0.004
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41 1999 Chr 8 28 NS
Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54[65] 1999 Chr 8 58 0.17
Hattinger et al, Br J Cancer 86, 1763-9[63] 2002 Chr 8 134 NS
Tarkannen et al, Cancer Genet Cytogenet 114, 35-41 1999 Chr 12 28 NS
Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54 [65] 1999 Chr 12 58 0.63
Hattinger et al, Br J Cancer 86, 1763-9[63] 2002 Chr 12 134 0.009
Ohali et al, J Clin Oncol 21, 3836-43[52] 2003 Telomerase activity 31 0.0001
Avigad et al, Clin Cancer Res 13 (19), 5777-83[54] 2007 Telomerase length 32 0.015
NS: not significant, Chr: Chromosome
Table 7 Outcome for biological markers: immunological
Author Year Biomarker Pt number P
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 IL-1ra 13 0.0001
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 sIL-2ra 13 0.005
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 IL-6 13 0.001
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 IL-8 13 0.0001
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 IL-10 13 0.01
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 TNF RI 13 0.001
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 TNF RII 13 0.01
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 M-CSF 13 0.01
Berghuis et al, J Pathol 218, 222-31[66] 2009 HLA class I 67 NS
NS: not significant
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marker of cell activity in the tumour that significantly
correlates with outcome. The mechanism for the activa-
tion of cell cycle appears unclear, but is presumably dri-
ven by other factors other that EWS-FLI1 translocation.
Loss of function of cell cycle dependent kinases (p16,
p14, p21) and other regulators of the cell cycle through
the p53 pathway (MDM2, p53), also appear deregulate
in a proportion of tumours and potentially are useful
prognostic markers. Importantly, activity of telomerase
appears significantly correlated with outcome as occurs
in many other tumours. There appears much interest in
Table 8 Outcome for biological markers: blood products
Author Year Biomarker Pt number P
Holzer et al, Med Pediatr Oncol 36 (6), 601-4[67] 2001 VEGF 6 NS
Pavlakovic et al, Int J Cancer 92, 756-60 [68] 2001 VEGF 4 0.017
Rutkowski et al, J Surg Oncol 84, 151-9[27] 2003 VEGF 13 NS
Fuchs et al, Clin Cancer Res 10, 1344-53[45] 2004 VEGF 31 0.0047
Jimeno et al, Pediatr Blood Cancer 49, 352-7[69] 2007 VEGF 16 NS
Kreuter et al, Eur J Cancer 42, 1904-11[47] 2006 VEGF-A 40 0.013
Kreuter et al, Eur J Cancer 42, 1904-11[47] 2006 VEGFR-1 40 0.946
Kreuter et al, Eur J Cancer 42, 1904-11[47] 2006 VEGFR-2 40 0.946
Aparicio et al, Oncology 55, 20-6[9] 1998 Lymphocyte count 116 0.0044
De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52[17] 2007 Lymphocyte count 24 0.001
De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52 [17] 2007 Platelet count 24 NS
De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52[17] 2007 Neutrophil count 24 NS
Aparicio et al, Oncology 55, 20-6[9] 1998 Erythrocyte sedimentation rate 116 0.02
Oberlin et al, B J Cancer 85 (11), 1646-54[26] 2001 Erythrocyte sedimentation rate 141 0.04
Yabe et al, Oncol Rep 19 (1), 129-34[70] 2008 Erythrocyte sedimentation rate 20 NS
NS: not significant
Table 9 Outcome for biological markers: remaining
Author Year Biomarker Pt number P
Craft et al, Eur J Cancer 33 (7), 1061-9[8] 1997 LDH 142 NS
Aparicio et al, Oncology 55, 20-6[9] 1998 LDH 116 0.001
Givens et al, Int J Oncol 14 (6), 1039-43[12] 1999 LDH 85 NS
Bacci et al, Oncol Rep 6 (4), 807-11[71] 1999 LDH 618 S
Luksch et al, Tumori 85 (2), 101-7[41] 1999 LDH 73 S
Bacci et al, J Clin Oncol 18, 4-11[13] 2000 LDH 359 0.0003
Matsunobu et al, Clin Cancer Res 10, 1003-12[29] 2004 LDH 21 NS
Bacci et al, Acta Oncol 45, 469-75[16] 2006 LDH 579 0.0005
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] 2007 LDH 28 0.99
Yabe et al, Oncol Rep 19 (1), 129-34[70] 2008 LDH 20 NS
Leavey et al, Pediatr Blood Cancer 51 (3), 334-8[18] 2008 LDH 262 0.0016
Xie et al, Chin J Cancer 29 (4), 420-4 2010 LDH 18 NS
Terrier et al, Eur J Cancer 31 (3), 307-14[36] 1995 Filigree pattern 315 0.044
Terrier et al, Eur J Cancer 31 (3), 307-14[36] 1995 Dark cells 315 0.043
Aparicio et al, Oncology 55, 20-6[9] 1998 Albumine levels 116 0.0006
Sollazzo et al, Tumori 85 (3), 167-73[56] 1999 c-myc 38 S
Ohali et al, Oncogene 23, 8997-9006[60] 2004 MTA1 20 0.003
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] 2007 NKX2-2 28 0.0017
Kikuta et al, Clin Cancer Res 15 (8), 2885-94[20] 2009 Nucleophosmin positivity 8 0.01
Meynet et al, Cancer Res 70 (9), 3730-8[55] 2010 Xg expression 97 0.047
S: significant, NS: not significant
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Ewing sarcoma, and in particular, chromosome 1 (Table
6). For example, recent evidence points to gain of 1q
and alteration in abundance of a gene product called
CDt2 involved in ubiquitination [7]. It is however diffi-
cult to objectively say anything about the other reported
markers because they may influence each other. This
appears most clear for tumour size and metastases,
w h e r eb i g g e rt u m o u r sm a yc o r r e l a t ew i t hah i g h e r
chance of having metastases. For biological markers it is
probably the same issue, but less clear because we don’t
really know their true experimental influence on tumour
genesis. For example, LDH levels are probably a reflec-
tion of cell turnover in larger tumours, and may be an
indirect measure of bulk of disease (comparing Table 2
versus Table 9). It is also more difficult to say anything
about biological markers because they haven’tb e e n
tested as extensively as phenotypic markers, and cer-
tainly they have not often been validated independently.
Results for most of these markers are only reported in 1
or 2 articles with sometimes small numbers of patients
and no statistical validation. To improve this situation it
would important to capture high quality clinical material
and clinical outcome to develop a bio-bank. We may be
able to test the most promising biomarkers from pre-
viously run studies and so define their significance.
E i t h e ram u l t i v a r i a t ea n a l y s i so rd a t am i n i n ga n a l y s i s
should be done to evaluate the way biomarkers affect
each other. The easiest way to achieve this objective is
by collecting material and outcome data from large
phase III trials. It is also important to standardize the
way material is collected and how the biomarkers are
compared. For example, the phenotypic marker tumour
site is the most often tested marker with results pub-
lished in 26 articles (data not shown). However it is not
possible to say anything about these results since differ-
ent tumour sites are compared in the reports. This is
also true for the marker age in which different age
groups are compared with each other, for example some
articles compare patients < 18 years vs > 18 years,
others < 30 years vs > 30 years (data not shown).
For markers of tumour growth, angiogenesis if often
quantified, but so far biomarker analysis has been pre-
dominantly limited to measurement of VEGF pathway
(Table 8). The immunological biological markers inter-
leukins and tumour necrosis factors seem very promis-
ing (Table 7). However these have all been tested in one
institute, with very small patient numbers and the data
doesn’t seem to be validated. Most of the biological
markers mentioned in the blood products group (Table
8) are probably surrogates for tumour size and they
should be validated in either a multivariate analysis or
Figure 3 Distribution of p related to patient number for the
biological markers related to cell cycle, karyotype,
immunological, blood products and remaining markers. The red
line shows the cut-off point of p = 0.05. Note, there is no line for
immunological phenotypic markers because for all the results p <
0.05.
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tive biological marker.
At the present time it is no possible to make a definite
list of biological biomarkers able to predict patient out-
come, mainly because these markers also have to be
stratified with respect to the major staging phenotypic
features, e.g. presence of metastasis and degree of histo-
logical response. It is also unclear what quality control
measure were used in the limited patient cohorts. Our
r e c o m m e n d a t i o nw o u l db ec o n t i n u ed i v i d ep a t i e n t s
according to their disease stage and also to use the phe-
notypic biomarkers metastasis, tumour size and histolo-
gical response. For biological biomarkers we would like
to validate previous work done on the markers for 9p21
locus and the involved genes and proteins, heat shock
proteins, telomerase related markers, interleukins,
tumour necrosis factors, VEGF pathway, lymphocyte
c o u n t ,M T A 1 ,S T E A P 1 ,C C N D 1 ,M D M - 2 ,K i - 6 7 ,p 5 3 ,
p27 and cadherin-11. At this time, neither phenotypic
(clinical) or biological biomarkers are utilised in stratifi-
cation of patients in clinical trials.
Lists of abbreviations
LDH: Lactate dehydrogenase; REMARK: Reporting recommendations for
tumour MARKer prognostic studies; ESFT: Sarcoma Family of Tumours; PNET:
Primitive Neuroectodermal.
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